EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
1.13.11.34 | 4,4'-(2,3-dimethyl)-1,4-butanediylbis-1,2-benzenediol | - |
Rattus norvegicus | |
1.13.11.34 | A-53162 | - |
Rattus norvegicus | |
1.13.11.34 | ABT 761 | CAS: 154355-76-7 | Rattus norvegicus | |
1.13.11.34 | additional information | classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 | Cavia porcellus | |
1.13.11.34 | additional information | classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 | Homo sapiens | |
1.13.11.34 | additional information | classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 | Oryctolagus cuniculus | |
1.13.11.34 | additional information | - |
Rattus norvegicus | |
1.13.11.34 | additional information | classes of 5-lipoxygenase inhibitors: 1. compounds that inhibit the enzyme via antioxidant mechanism - NGDA, BW755c, AA-861, ICI-207968, and A-53612. High toxicity, unacceptable for clinical development. 2. compounds that interact with the non-heme iron moiety of the enzyme - BW-A4A, and ABT-761 both effective in asthma and zileuton. 3. nonredox competitive inhibitors - ZD-2138 and L-697198 | Sus scrofa | |
1.13.11.34 | ZD 2138 | - |
Homo sapiens | |
1.13.11.34 | ZD 2138 | - |
Rattus norvegicus | |
1.13.11.34 | zileuton | - |
Homo sapiens | |
1.13.11.34 | zileuton | - |
Rattus norvegicus |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.13.11.34 | Cavia porcellus | - |
- |
- |
1.13.11.34 | Homo sapiens | - |
- |
- |
1.13.11.34 | Oryctolagus cuniculus | - |
- |
- |
1.13.11.34 | Rattus norvegicus | - |
- |
- |
1.13.11.34 | Sus scrofa | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
1.13.11.34 | leukemia cell | - |
Rattus norvegicus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.13.11.34 | arachidonate + O2 | i.e. 5,8,11,14-eicosatetraenoic acid | Cavia porcellus | (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate | - |
? | |
1.13.11.34 | arachidonate + O2 | i.e. 5,8,11,14-eicosatetraenoic acid | Homo sapiens | (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate | - |
? | |
1.13.11.34 | arachidonate + O2 | i.e. 5,8,11,14-eicosatetraenoic acid | Rattus norvegicus | (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate | - |
? | |
1.13.11.34 | arachidonate + O2 | i.e. 5,8,11,14-eicosatetraenoic acid | Sus scrofa | (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate | - |
? | |
1.13.11.34 | arachidonate + O2 | i.e. 5,8,11,14-eicosatetraenoic acid | Oryctolagus cuniculus | (6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate | - |
? |